Invitro and in-vivo evaluation of optimized sustain release nanoparticulate tablet of vildagliptin

Abstract

The objective of the present investigation was to evaluate pharmacodynamics and pharmacokinetic parameters of optimized nanoparticulate sustain release tablet of Vildagliptin prepared by using Anti-solvent method containing polymer HPMC K15M and Sodium Alginate in a ratio of 1:0.75. The optimized nanoparticulate tablet test formulation demonstrated favorable in-vitro drug release characteristics. The nanoparticulate formulation was orally administered to rat and blood samples were used to determine pharmacokinetic parameters, which were compared with pharmacokinetic parameters of the marketed tablet formulation. The relative bioavailability of Nanoparticulate tablet was found to be increased about 1.2 times in comparison to that of the marketed tablet. The results for invitro drug release and in vivo antidiabetic activity for 24 hours were also found very significant. As per results obtained from in vitro and in vivo studies, nanoparticulate tablet of Vildagliptin may prove to be a potential contender for secure and efficient sustained drug release over an absolute phase of time which can decrease dosing frequency.